Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1109-1119

  Rand, M L ^a,b,c   Wang, H ^a,b   Pluthero, F G ^a,b   Stafford, A R ^d   Ni, R ^d   Vaezzadeh, N ^d   Allison, A C ^e   Kahr, W H A ^a,b,c   Weitz, J I ^d   Gross, P L ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e Alavita Pharmaceuticals Inc   (United States)

Author keywords

Annexin A5; Diannexin; Phosphatidylserine; Platelets; Thrombin generation; Thrombus formation

Indexed keywords

ANNEXIN; DIANNEXIN; FIBRIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BINDING AFFINITY; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; CREMASTER MUSCLE; FLOW CYTOMETRY; HEMATOLOGICAL PROCEDURE; HEMOSTASIS; HUMAN; INTRAVITAL VIDEOMICROSCOPY; LIPID BILAYER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SURFACE PLASMON RESONANCE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY; THROMBOGENESIS; THROMBOGRAPHY;

ANIMALS; ANNEXIN A5; BLOOD COAGULATION; BLOOD PLATELETS; DIMERIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HEMOSTASIS; HUMANS; LIPID BILAYERS; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, VIDEO; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SURFACE PLASMON RESONANCE; THROMBELASTOGRAPHY; THROMBIN; THROMBOSIS; TIME FACTORS;

EID: 84861659305     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04716.x     Document Type: Article

References (52)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
2. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
3. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-93.
4. Bevers EM, Williamson PL. Phospholipid scramblase: an update. FEBS Lett 2010; 584: 2724-30.
5. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636: 119-28.
6. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 2009; 35: 233-41.
7. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 9(Suppl. 1): 76-91.
8. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468: 834-8.
9. Castoldi E, Collins PW, Williamson PL, Bevers EM. Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 2011; 117: 4399-400.
10. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta 2008; 1783: 953-63.
11. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-65.
12. Wolfs JL, Comfurius P, Rasmussen JT, Keuren JF, Lindhout T, Zwaal RF, Bevers EM. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62: 1514-25.
13. Leung R, Gwozdz AM, Wang H, Bang KW, Packham MA, Freedman J, Rand ML. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost 2007; 5: 560-70.
14. Gwozdz AM, Leung R, Wang H, Bang KW, Packham MA, Freedman J, Rand ML. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects. Thromb Haemost 2010; 103: 1218-27.
15. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus formation. Thromb Haemost 2009; 102: 1149-56.
16. Furman MI, Krueger LA, Frelinger AL 3rd, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
17. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort MA, Rosing J, Bock PE, Watson SP, Heemskerk JW. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 2007; 27: 2484-90.
18. Hayashi T, Mogami H, Murakami Y, Nakamura T, Kanayama N, Konno H, Urano T. Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo. Pflugers Arch 2008; 456: 1239-51.
19. Galan AM, van Heerde WL, Escolar G, Ordinas A, Sixma J, de Groot PG. Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. Eur J Clin Invest 2006; 36: 633-9.
20. Romisch J, Seiffge D, Reiner G, Paques EP, Heimburger N. In-vivo antithrombotic potency of placenta protein 4 (annexin V). Thromb Res 1991; 61: 93-104.
21. van Ryn-McKenna J, Merk H, Muller TH, Buchanan MR, Eisert WG. The effects of heparin and annexin V on fibrin accretion after injury in the jugular veins of rabbits. Thromb Haemost 1993; 69: 227-30.
22. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96: 2339-47.
23. Sun J, Bird P, Salem HH. Interaction of annexin V and platelets: effects on platelet function and protein S binding. Thromb Res 1993; 69: 289-96.
24. Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost 2008; 6: 1167-74.
25. Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007; 97: 478-86.
26. Wever KE, Wagener FA, Frielink C, Boerman OC, Scheffer GJ, Allison A, Masereeuw R, Rongen GA. Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS ONE 2011; 6: e24276.
27. Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979; 18: 4419-25.
28. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-10.
29. Ames BN. Assay of inorganic phosphate, total phosphate, and phosphatases. Methods Enzymol 1966; VIII: 115-8.
30. Molnar J, Lorand L. Studies on apyrases. Arch Biochem Biophys 1961; 93: 353-63.
31. Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3-11.
32. Kinlough-Rathbone RL, Perry DW, Rand ML, Packham MA. Most apyrase preparations are impure and contain inhibitors of cathepsin G: suggestions for use of apyrase in preparation and stabilization of platelet suspensions. Thromb Haemost 1999; 81: 849-50.
33. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-5.
34. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005; 78: 1318-26.
35. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8: 1175-81.
36. Bai X, Weitz JI, Gross PL. Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. Thromb Haemost 2009; 102: 1212-8.
37. Gross PL, Ni R, Esposito B, Rand ML, Weitz JI. The dynamics of platelet activation in vivo. J Thromb Haemost 2009; 7(Suppl. 2): PP-TH-009.
38. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, Herbert JM, Lemke G, Goff SP, Matsushima GK, Earp HS, Vesin C, Hoylaerts MF, Plaisance S, Collen D, Conway EM, Wehrle-Haller B, Carmeliet P. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005; 115: 237-46.
39. Vanschoonbeek K, Feijge MA, van Kampen RJ, Kenis H, Hemker HC, Giesen PL, Heemskerk JW. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-84.
40. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J 1994; 302(Pt 1):305-12.
41. Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, Willems GM. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-12.
42. Romisch J, Schorlemmer U, Fickenscher K, Paques EP, Heimburger N. Anticoagulant properties of placenta protein 4 (annexin V). Thromb Res 1990; 60: 355-66.
43. Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombosis models. Arterioscler Thromb Vasc Biol 2010; 30: 900-8.
44. Kuijpers MJ, Munnix IC, Cosemans JM, Vlijmen BV, Reutelingsperger CP, Egbrink MO, Heemskerk JW. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo. Differential sensitivity to thrombin inhibition. Microcirculation 2008; 15: 269-82.
45. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
46. Teoh NC, Ito Y, Field J, Bethea NW, Amr D, McCuskey MK, McCuskey RS, Farrell GC, Allison AC. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology 2007; 133: 632-46.
47. Shen XD, Ke B, Zhai Y, Tsuchihashi SI, Gao F, Duarte S, Coito A, Busuttil RW, Allison AC, Kupiec-Weglinski JW. Diannexin, a novel annexin V homodimer, protects rat liver transplants against cold ischemia-reperfusion injury. Am J Transplant 2007; 7: 2463-71.
48. Molski M, Groth A, Allison AC, Hendrickson M, Siemionow M. Diannexin treatment decreases ischemia-reperfusion injury at the endothelial cell level of the microvascular bed in muscle flaps. Ann Plast Surg 2009; 63: 564-71.
49. Hale SL, Allison AC, Kloner RA. Diannexin reduces no-reflow after reperfusion in rabbits with large ischemic myocardial risk zones. Cardiovasc Ther 2011; 29: e42-52.
50. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A 2009; 106: 3794-9.
51. Cheng EY, Sharma VK, Chang C, Ding R, Allison AC, Leeser DB, Suthanthiran M, Yang H. Diannexin decreases inflammatory cell infiltration into the islet graft, reduces beta-cell apoptosis, and improves early graft function. Transplantation 2010; 90: 709-16.
52. Cooper M, Kapur S, Stratta R. Diannexin, a novel ischemia/reperfusion therapeutic agent, reduces delayed graft function (DGF) in renal transplant recipients from marginal donors. Am J Transplant 2010; 10: S83.